Catalent Inc (NASDAQ:CTLT) has been assigned a consensus rating of “Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $41.63.

A number of analysts recently weighed in on the stock. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Wells Fargo & Company upped their target price on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Bank of America Corporation reaffirmed a “buy” rating and set a $45.00 target price (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Zacks Investment Research raised shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 target price on the stock in a report on Tuesday, July 4th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $45.00 target price on shares of Catalent in a report on Tuesday, August 29th.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of hedge funds have recently added to or reduced their stakes in the business. Advisor Group Inc. grew its stake in Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares in the last quarter. Stifel Financial Corp grew its stake in Catalent by 0.9% in the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after buying an additional 96 shares in the last quarter. Aperio Group LLC grew its stake in Catalent by 0.8% in the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after buying an additional 190 shares in the last quarter. Capstone Asset Management Co. grew its stake in Catalent by 2.3% in the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after buying an additional 230 shares in the last quarter. Finally, People s United Financial Inc. grew its stake in Catalent by 1.9% in the 2nd quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after buying an additional 356 shares in the last quarter.

Catalent (NASDAQ CTLT) traded down 1.34% during mid-day trading on Wednesday, hitting $42.02. 258,379 shares of the company traded hands. The firm has a market capitalization of $5.26 billion and a P/E ratio of 48.30. The firm has a 50 day moving average of $41.37 and a 200 day moving average of $36.56. Catalent has a one year low of $21.83 and a one year high of $43.39.

Catalent (NASDAQ:CTLT) last posted its earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.08. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a net margin of 10.02% and a return on equity of 36.29%. Catalent’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 EPS. Equities research analysts expect that Catalent will post $1.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Catalent Inc (CTLT) Receives Average Rating of “Buy” from Analysts” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/01/catalent-inc-ctlt-receives-average-rating-of-buy-from-analysts.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.